CR20200206A - Conjugados de fármaco-anticuerpo activable anti-cd71 y métodos de uso de estos - Google Patents

Conjugados de fármaco-anticuerpo activable anti-cd71 y métodos de uso de estos

Info

Publication number
CR20200206A
CR20200206A CR20200206A CR20200206A CR20200206A CR 20200206 A CR20200206 A CR 20200206A CR 20200206 A CR20200206 A CR 20200206A CR 20200206 A CR20200206 A CR 20200206A CR 20200206 A CR20200206 A CR 20200206A
Authority
CR
Costa Rica
Prior art keywords
methods
drug conjugates
antibody drug
activatable antibody
activatable antibodies
Prior art date
Application number
CR20200206A
Other languages
English (en)
Inventor
Jonathan Alexander Terrett
Marvin Robert Leanna
Sahana Bose
Jennifer Hope Richardson
Laura Patterson Serwer
Susan E Morgan-Lappe
Tracy Henriques
Sherry L Ralston
Ilaria Badagnani
Shweta Singh
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of CR20200206A publication Critical patent/CR20200206A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

<p>La invención se refiere en general a anticuerpos activables conjugados que se fijan a CD71 en su forma activa y a métodos para elaborar y usar estos anticuerpos activables conjugados anti-CD71 en una variedad de indicaciones terapéuticas, de diagnóstico y profilácticas</p>
CR20200206A 2017-10-14 2018-10-12 Conjugados de fármaco-anticuerpo activable anti-cd71 y métodos de uso de estos CR20200206A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762572467P 2017-10-14 2017-10-14
PCT/US2018/055733 WO2019075417A1 (en) 2017-10-14 2018-10-12 CONJUGATES OF MEDICAMENT ANTI-CD71 ACTIVATED ANTIBODIES AND METHODS OF USE

Publications (1)

Publication Number Publication Date
CR20200206A true CR20200206A (es) 2021-02-18

Family

ID=64110112

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20200206A CR20200206A (es) 2017-10-14 2018-10-12 Conjugados de fármaco-anticuerpo activable anti-cd71 y métodos de uso de estos

Country Status (34)

Country Link
US (3) US20190111150A1 (es)
EP (2) EP3834846A1 (es)
JP (2) JP7374891B2 (es)
KR (4) KR20230070046A (es)
CN (1) CN111278467A (es)
AR (1) AR115178A1 (es)
AU (1) AU2018346969A1 (es)
BR (1) BR112020007302B1 (es)
CA (1) CA3077730A1 (es)
CL (1) CL2020000977A1 (es)
CO (1) CO2020005685A2 (es)
CR (1) CR20200206A (es)
CY (1) CY1123968T1 (es)
DK (1) DK3691692T3 (es)
DO (1) DOP2023000150A (es)
EC (1) ECSP20025198A (es)
ES (1) ES2864013T3 (es)
HR (1) HRP20210436T8 (es)
HU (1) HUE054037T2 (es)
IL (1) IL273586A (es)
LT (1) LT3691692T (es)
MA (1) MA50752B1 (es)
MD (1) MD3691692T2 (es)
MX (1) MX2020003723A (es)
PE (1) PE20210125A1 (es)
PL (1) PL3691692T3 (es)
PT (1) PT3691692T (es)
RS (1) RS61596B1 (es)
RU (2) RU2771292C2 (es)
SG (1) SG11202003378WA (es)
SI (1) SI3691692T1 (es)
TW (2) TW202330039A (es)
UY (1) UY37931A (es)
WO (1) WO2019075417A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130116404A1 (en) 2011-11-08 2013-05-09 Case Western Reserve University Targeted non-invasive imaging probes of egfr expressing cells
LT3292149T (lt) * 2015-05-04 2022-03-10 Cytomx Therapeutics, Inc. Aktyvinami antikūnai prieš cd71 ir jų naudojimo būdai
WO2019183633A1 (en) 2018-03-23 2019-09-26 Case Western Reserve Univeristy Psma targeted conjugate compounds and uses thereof
JP2023520821A (ja) * 2020-04-08 2023-05-19 アリアダ セラピューティクス，インコーポレイテッド 血液脳関門送達のための組成物および方法
WO2021207657A1 (en) * 2020-04-09 2021-10-14 Cytomx Therapeutics, Inc. Compositions containing activatable antibodies
AU2022388735A1 (en) 2021-11-09 2024-05-30 Case Western Reserve University Psma targeted conjugate compounds and uses thereof
WO2024026474A1 (en) * 2022-07-29 2024-02-01 Regeneron Pharmaceuticals, Inc. Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988001513A1 (en) 1986-08-28 1988-03-10 Teijin Limited Cytocidal antibody complex and process for its preparation
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
DE69329503T2 (de) 1992-11-13 2001-05-03 Idec Pharma Corp Therapeutische Verwendung von chimerischen und markierten Antikörpern, die gegen ein Differenzierung-Antigen gerichtet sind, dessen Expression auf menschliche B Lymphozyt beschränkt ist, für die Behandlung von B-Zell-Lymphoma
CA2620886C (en) 2005-08-31 2017-03-14 The Regents Of The University Of California Cellular libraries of peptide sequences (clips) and methods of using the same
CA2697032C (en) 2007-08-22 2021-09-14 The Regents Of The University Of California Activatable binding polypeptides and methods of identification and use thereof
EA201692127A1 (ru) * 2007-11-07 2017-08-31 Селлдекс Терапьютикс Инк. Антитела, связывающиеся с человеческим dec-205
EP2385955B1 (en) 2009-01-12 2020-08-12 CytomX Therapeutics, Inc. Modified antibody compositions, methods of making and using thereof
EP2424891B1 (en) * 2009-04-29 2014-06-11 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Erg monoclonal antibodies
WO2010129609A2 (en) 2009-05-07 2010-11-11 The Regents Of The University Of California Antibodies and methods of use thereof
RU2636029C2 (ru) * 2011-02-01 2017-11-17 Генмаб А/С Человеческие антитела и конъюгаты антитело-препарат против cd74
TR201819828T4 (tr) * 2012-01-31 2019-01-21 Sbi Biotech Co Ltd Anti-fosfolipaz d4 antikoru.
WO2014026136A2 (en) 2012-08-10 2014-02-13 Cytomx Therapeutics, Inc. Protease-resistant systems for polypeptide display and methods of making and using thereof
CN103145847B (zh) * 2013-02-05 2014-05-21 浙江大学 一种抗cd20抗体-海兔毒素偶联物及其制备方法和应用
SI3088419T1 (sl) * 2013-12-25 2019-01-31 Daiichi Sankyo Company Zdravilni konjugat anti trop2 protitelesa
LT3292149T (lt) 2015-05-04 2022-03-10 Cytomx Therapeutics, Inc. Aktyvinami antikūnai prieš cd71 ir jų naudojimo būdai
CN106237341B (zh) * 2016-07-12 2019-07-30 浙江大学 一种抗体偶联药物及其制备方法和应用

Also Published As

Publication number Publication date
JP7374891B2 (ja) 2023-11-07
SI3691692T1 (sl) 2021-04-30
HRP20210436T8 (hr) 2022-01-07
RU2020115713A3 (es) 2022-02-25
MA50752A (fr) 2020-08-12
KR102385495B1 (ko) 2022-04-15
MA50752B1 (fr) 2021-03-31
KR20230070046A (ko) 2023-05-19
JP2020537649A (ja) 2020-12-24
BR112020007302A2 (pt) 2020-09-29
CO2020005685A2 (es) 2020-05-15
DOP2023000150A (es) 2023-08-31
KR20230004932A (ko) 2023-01-06
EP3691692B8 (en) 2021-05-26
CL2020000977A1 (es) 2020-09-11
KR102529359B1 (ko) 2023-05-09
WO2019075417A1 (en) 2019-04-18
ECSP20025198A (es) 2020-06-30
RS61596B1 (sr) 2021-04-29
BR112020007302B1 (pt) 2023-01-31
HRP20210436T1 (hr) 2021-04-30
KR20220045088A (ko) 2022-04-12
RU2020115713A (ru) 2021-11-16
PL3691692T3 (pl) 2021-07-19
MX2020003723A (es) 2020-07-22
US20210145978A1 (en) 2021-05-20
RU2771292C2 (ru) 2022-04-29
AR115178A1 (es) 2020-12-09
KR20200070324A (ko) 2020-06-17
EP3691692A1 (en) 2020-08-12
CY1123968T1 (el) 2022-05-27
HUE054037T2 (hu) 2021-08-30
RU2022111211A (ru) 2022-05-05
DK3691692T3 (da) 2021-03-22
EP3691692B1 (en) 2020-12-30
TWI780237B (zh) 2022-10-11
JP2024012366A (ja) 2024-01-30
SG11202003378WA (en) 2020-05-28
PE20210125A1 (es) 2021-01-19
US20240115724A1 (en) 2024-04-11
CA3077730A1 (en) 2019-04-18
ES2864013T3 (es) 2021-10-13
IL273586A (en) 2020-05-31
MD3691692T2 (ro) 2021-05-31
EP3834846A1 (en) 2021-06-16
AU2018346969A1 (en) 2020-04-23
TW201927815A (zh) 2019-07-16
PT3691692T (pt) 2021-03-29
TW202330039A (zh) 2023-08-01
UY37931A (es) 2019-04-30
US20190111150A1 (en) 2019-04-18
CN111278467A (zh) 2020-06-12
LT3691692T (lt) 2021-05-10

Similar Documents

Publication Publication Date Title
CR20200206A (es) Conjugados de fármaco-anticuerpo activable anti-cd71 y métodos de uso de estos
ZA201707645B (en) Anti-cd71 antibodies, activatable anti-cd71 antibodies, and methods of use thereof
MX2020002198A (es) Anticuerpos anti-cd166 activables y métodos de uso de los mismos.
MX2021005116A (es) Anticuerpos activables anti-cd166 y metodos de uso de estos.
PH12019501824A1 (en) Anti-gprc5d antibody and molecule comprising the antibody
MX2021014735A (es) Anticuerpos anti-cd166, anticuerpos anti-cd166 activables, y metodos de uso de los mismos.
PH12019501330A1 (en) Antibody drug conjugates for ablating hematopoietic stem cells
MX2018014175A (es) Conjugados de anticuerpo-fármaco anti-cmet y métodos para su uso.
MA38396A1 (fr) Anticorps medicamenteux conjugues et leurs compositions pharmaceutiques pour traiter un cancer positif a ckit
WO2015066279A3 (en) Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
WO2009140348A3 (en) Anti-il-6/il-6r antibodies and methods of use thereof
EP3580239A4 (en) ANTIBODY ANTI-ILT3 AND ANTIBODY-DRUG CONJUGATES
MX347893B (es) Conjugados de farmaco y anticuerpo humano contra factor de tejido.
WO2014163714A3 (en) Antibody drug conjugates
MX2019011624A (es) Metodos y composiciones para la reduccion de la inmunogenicidad.
MX2016008191A (es) Conjugados de toxina polipeptidica-anticuerpo unidos covalentemente.
EP3612567A4 (en) ANTI-VTCN1 ANTIBODIES AND ANTIBODY INGREDIENT CONJUGATES
MX2020008730A (es) Regímenes de dosificación de anticuerpo b7-h4.
EP3753952A4 (en) EGFRVIII ANTIBODY AND CONJUGATE, METHOD FOR THE PREPARATION AND USE THEREOF
PH12020551556A1 (en) Drug conjugates of cmet monoclonal binding agents, and uses thereof
EP3601360A4 (en) ANTI-TMEFF1 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES
UA109148C2 (uk) Композиції на основі антитіла проти vegfr-3
EA202191243A1 (ru) Активируемые антитела к cd166 и способы их применения
MY193448A (en) Anti-cd166 antibodies, and activatable anti-cd166 antibodies, and methods of use thereof
EA201892068A1 (ru) Конъюгаты napi2b-нацеленное антитело-лекарственное средство и способы их применения